ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Maraviroc

Also written as “Maraviroc (UK-427,857)”, “maraviroc” and “Maraviroc + Fosamprenavir/ritonavir”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · HIV Infections · Post-Acute COVID-19 Syndrome · Infections · Arthritis, Rheumatoid, led by 4 companies.

Drug pageMaraviroc: every studyAll 118 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 23, 200826 company-led studies, 1 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only220 open or runningphase 4since Apr 23, 2008Dec 6, 2004none ahead
Pfizer20 open or runningphase 2since Jan 25, 2007Jan 25, 2007none ahead
HealthBioits history only11 open or runningphase 3since May 7, 2025May 7, 2025Dec 1, 2026phase 3 · NCT06974084
Population Councilits history only10 open or runningphase 1since Jan 20, 2015Jan 20, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2007First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT00427934 · 128 enrolled · United States, Australia, Germany and more
  2. Oct 30, 2008Phase 1 study in Healthy VolunteersNCT00783484 · 37 enrolled · Belgium

TargetBeta

CCR5 →read by rule
“A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV)”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule

Other programs on CCR5

ProgramCompanyFurthest phaseStudies
leronlimabruleCytoDynphase 320

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00783484Healthy Volunteers · Belgium1CompletedMay 200937
NCT00427934Arthritis, Rheumatoid · United States, Australia, Germany and more2TerminatedOct 2008128

How it is read

Names in the registry

  • “Maraviroc”, 23 entries
  • “Maraviroc (UK-427,857)”, 8 entries
  • “maraviroc”, 5 entries
  • “Maraviroc + Fosamprenavir/ritonavir”, 4 entries
  • “Maraviroc +PF-03716539”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.